{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T07:12:22Z","timestamp":1791616342193,"version":"4.3.4"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,4]]},"abstract":"<jats:sec>\n            <jats:title>Background.<\/jats:title>\n            <jats:p>Systemic hypertension is prevalent in heart transplant recipients and has been partially attributed to treatment with calcineurin inhibitors (CNIs). SCandinavian HEart transplant De-novo stUdy with earLy calcineurin inhibitors avoidancE trial was the first randomized trial to study early withdrawal of CNIs in de novo heart transplant recipients, comparing an everolimus-based immunosuppressive regimen with conventional CNI-based treatment. As a prespecified secondary endpoint, blood pressure was repeatedly compared across treatment arms.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods.<\/jats:title>\n            <jats:p>The The SCandinavian HEart transplant De-novo stUdy with earLy calcineurin inhibitors avoidancE trial was a prospective, multicenter, randomized, controlled, parallel-group, open-label trial in de novo adult heart transplant recipients, undertaken at transplant centers in Scandinavia. Blood pressure was assessed with 24-hour ambulatory blood pressure monitoring up to 3 years after heart transplantation (HTx) in 83 patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results.<\/jats:title>\n            <jats:p>Overall, systolic blood pressure fell with time, from 138 \u00b1 15\u2009mm Hg 2 weeks after HTx to 134 \u00b1 11\u2009mm Hg after 12 months and 132 \u00b1 14\u2009mm Hg after 36 months (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.003). Diastolic blood pressure did not change over time. After 12 months, there was a numerically larger fall in systolic blood pressure in the everolimus arm (between-group difference 8\u2009mm Hg; <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.053), and after 36 months, there was a significant between group difference of 13\u2009mm Hg (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.02) in favor of everolimus.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions.<\/jats:title>\n            <jats:p>In this first, randomized trial with early CNI avoidance in de novo HTx recipients, we observed a modest fall in systolic blood pressure over the first 1 to 3 years after transplantation. The fall in systolic blood pressure was more pronounced in patients allocated to everolimus.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/tp.0000000000002445","type":"journal-article","created":{"date-parts":[[2018,9,29]],"date-time":"2018-09-29T07:06:42Z","timestamp":1538204802000},"page":"781-788","source":"Crossref","is-referenced-by-count":13,"title":["Blood Pressure in De Novo Heart Transplant Recipients Treated With Everolimus Compared With a Cyclosporine-based Regimen: Results From the Randomized SCHEDULE Trial"],"prefix":"10.1097","volume":"103","author":[{"given":"Arne K.","family":"Andreassen","sequence":"first","affiliation":[{"name":"Department of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway."},{"name":"Faculty of Medicine, University of Oslo, Oslo, Norway."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaspar","family":"Broch","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Eiskj\u00e6r","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Aarhus University Hospital, Skejby, Denmark."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristjan","family":"Karason","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Einar","family":"Gude","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorte","family":"M\u00f8lbak","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Aarhus University Hospital, Skejby, Denmark."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenche","family":"Stueflotten","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Gullestad","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway."},{"name":"Faculty of Medicine, University of Oslo, Oslo, Norway."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20231002","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/0002-9149(90)90035-Y","article-title":"Cardiac transplant hypertension.","volume":"65","author":"Starling","year":"1990","journal-title":"Am J Cardiol"},{"key":"R2-20231002","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jash.2011.07.003","article-title":"Management of hypertension in the transplant patient.","volume":"5","author":"Weir","year":"2011","journal-title":"J Am Soc Hypertens"},{"key":"R3-20231002","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1161\/01.CIR.0000151609.60618.3C","article-title":"Drug therapy in the heart transplant recipient: part III: common medical problems.","volume":"111","author":"Lindenfeld","year":"2005","journal-title":"Circulation"},{"key":"R4-20231002","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1097\/TP.0000000000001432","article-title":"Recent advances in mammalian target of rapamycin inhibitor use in heart and lung transplantation.","volume":"100","author":"Fine","year":"2016","journal-title":"Transplantation"},{"issue":"2S Suppl 1","key":"R5-20231002","doi-asserted-by":"crossref","first-page":"s27","DOI":"10.1097\/TP.0000000000001921","article-title":"mTOR inhibition and clinical transplantation.","volume":"102","author":"Zuckermann","year":"2018","journal-title":"Heart Transplant"},{"key":"R6-20231002","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.healun.2016.08.017","article-title":"The registry of the International Society for Heart and Lung Transplantation: thirty-third adult heart transplantation report\u20142016; focus theme: primary diagnostic indications for transplant.","volume":"35","author":"Lund","year":"2016","journal-title":"J Heart Lung Transplant"},{"key":"R7-20231002","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1111\/ajt.12809","article-title":"Everolimus initiation and early calcineurin inhibitor withdrawal in heart transplant recipients: a randomized trial.","volume":"14","author":"Andreassen","year":"2014","journal-title":"Am J Transplant"},{"key":"R8-20231002","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1111\/ajt.13588","article-title":"Everolimus initiation with early calcineurin inhibitor withdrawal in de novo heart transplant recipients: three-year results from the randomized SCHEDULE study.","volume":"16","author":"Andreassen","year":"2016","journal-title":"Am J Transplant"},{"key":"R9-20231002","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.ejcts.2003.11.030","article-title":"Renal recovery after conversion to a calcineurin inhibitor-free immunosuppression in late cardiac transplant recipients.","volume":"25","author":"Groetzner","year":"2004","journal-title":"Eur J Cardiothorac Surg"},{"key":"R10-20231002","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.healun.2007.01.017","article-title":"Calcineurin inhibitor-free immunosuppression using everolimus (Certican) in maintenance heart transplant recipients: 6 months\u2019 follow-up.","volume":"26","author":"Rothenburger","year":"2007","journal-title":"J Heart Lung Transplant"},{"key":"R11-20231002","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1161\/01.HYP.35.3.844","article-title":"Prognostic value of ambulatory blood pressure: current evidence and clinical implications.","volume":"35","author":"Verdecchia","year":"2000","journal-title":"Hypertension"},{"key":"R12-20231002","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/HJH.0b013e32834de621","article-title":"Ambulatory blood pressure monitoring in Australia: 2011 consensus position statement.","volume":"30","author":"Head","year":"2012","journal-title":"J Hypertens"},{"key":"R13-20231002","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1097\/TP.0000000000001706","article-title":"Effect of calcineurin inhibitor-free, everolimus-based immunosuppressive regimen on albuminuria and glomerular filtration rate after heart transplantation.","volume":"101","author":"Nelson","year":"2017","journal-title":"Transplantation"},{"key":"R14-20231002","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1097\/00041552-199509000-00013","article-title":"Hypertension after cardiac transplantation: pathophysiology and management.","volume":"4","author":"Sander","year":"1995","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"R15-20231002","doi-asserted-by":"crossref","first-page":"437","DOI":"10.2165\/00002018-199920050-00004","article-title":"Cyclosporin-induced hypertension: incidence, pathogenesis and management.","volume":"20","author":"Taler","year":"1999","journal-title":"Drug Saf"},{"key":"R16-20231002","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1161\/01.CIR.0000033973.06059.04","article-title":"Oral everolimus inhibits in-stent neointimal growth.","volume":"106","author":"Farb","year":"2002","journal-title":"Circulation"},{"key":"R17-20231002","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1161\/01.CIR.0000057979.36322.88","article-title":"Rapamycin attenuates load-induced cardiac hypertrophy in mice.","volume":"107","author":"Shioi","year":"2003","journal-title":"Circulation"},{"key":"R18-20231002","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1093\/eurheartj\/ehn407","article-title":"Sirolimus affects cardiomyocytes to reduce left ventricular mass in heart transplant recipients.","volume":"29","author":"Kushwaha","year":"2008","journal-title":"Eur Heart J"},{"key":"R19-20231002","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1056\/NEJMoa022171","article-title":"Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients.","volume":"349","author":"Eisen","year":"2003","journal-title":"N Engl J Med"},{"key":"R20-20231002","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.athoracsur.2013.09.031","article-title":"Prospective study of everolimus with calcineurin inhibitor-free immunosuppression after heart transplantation: results at four years.","volume":"97","author":"Engelen","year":"2014","journal-title":"Ann Thorac Surg"},{"key":"R21-20231002","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1016\/j.transproceed.2014.09.034","article-title":"Inadequate blood pressure control in orthotopic heart transplant: is there a role of kidney function and immunosuppressive regimen?","volume":"46","author":"Wasilewski","year":"2014","journal-title":"Transplant Proc"},{"key":"R22-20231002","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1536\/ihj.15-320","article-title":"Everolimus attenuates myocardial hypertrophy and improves diastolic function in heart transplant recipients.","volume":"57","author":"Imamura","year":"2016","journal-title":"Int Heart J"},{"key":"R23-20231002","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1016\/j.healun.2005.04.002","article-title":"The importance of 24 hour ambulatory blood pressure monitoring after thoracic organ transplantation.","volume":"24","author":"Walker","year":"2005","journal-title":"J Heart Lung Transplant"},{"key":"R24-20231002","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1399-0012.2011.01569.x","article-title":"Ambulatory blood pressure monitoring in solid organ transplantation.","volume":"26","author":"Ramesh Prasad","year":"2012","journal-title":"Clin Transplant"},{"key":"R25-20231002","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/0002-9149(94)90158-9","article-title":"Decreased circadian blood pressure variation up to three years after heart transplantation.","volume":"73","author":"Idema","year":"1994","journal-title":"Am J Cardiol"},{"key":"R26-20231002","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/0002-9149(92)90508-V","article-title":"Reappearance of a normal circadian rhythm of blood pressure after cardiac transplantation.","volume":"69","author":"van de Borne","year":"1992","journal-title":"Am J Cardiol"},{"key":"R27-20231002","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1097\/TP.0000000000001739","article-title":"Cardiovascular parameters to 2 years after kidney transplantation following early switch to everolimus without calcineurin inhibitor therapy: an analysis of the randomized ELEVATE study.","volume":"101","author":"Holdaas","year":"2017","journal-title":"Transplantation"},{"key":"R28-20231002","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1097\/TP.0000000000002023","article-title":"Influence of blood pressure and calcineurin inhibitors on kidney function after heart or liver transplantation.","volume":"102","author":"Morath","year":"2018","journal-title":"Transplantation"},{"key":"R29-20231002","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1136\/bmj.39548.738368.BE","article-title":"Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials.","volume":"336","author":"Turnbull","year":"2008","journal-title":"BMJ"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00007890-201904000-00029","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T05:37:53Z","timestamp":1696225073000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007890-201904000-00029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000002445","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]}}}